Alto Neuroscience, Inc. Common Stock (ANRO)

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.

Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies.

ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024.

Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors.

ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024.

Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia.

The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning!

Amer Sports, the maker of Wilson tennis rackets and a host of other sports equipment, raised about $1.37 billion in its initial public offering, which was priced below the previously expected $16-$18 range. This was yet another disappointing IPO.